Business Description
Daewoong Pharmaceutical Co Ltd
ISIN : KR7069620003
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.31 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 0.58 | |||||
Debt-to-EBITDA | 2.37 | |||||
Interest Coverage | 9.01 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.34 | |||||
Beneish M-Score | -2.49 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.7 | |||||
3-Year EBITDA Growth Rate | 37 | |||||
3-Year EPS without NRI Growth Rate | 130.7 | |||||
3-Year Book Growth Rate | 9.2 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.9 | |||||
9-Day RSI | 47.67 | |||||
14-Day RSI | 46.53 | |||||
6-1 Month Momentum % | 6.7 | |||||
12-1 Month Momentum % | 1.96 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.86 | |||||
Quick Ratio | 0.5 | |||||
Cash Ratio | 0.21 | |||||
Days Inventory | 121.07 | |||||
Days Sales Outstanding | 36.45 | |||||
Days Payable | 50.97 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | -2.41 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 50.04 | |||||
Operating Margin % | 8.91 | |||||
Net Margin % | 8.85 | |||||
FCF Margin % | -1.47 | |||||
ROE % | 17.74 | |||||
ROA % | 7.3 | |||||
ROIC % | 8.4 | |||||
ROC (Joel Greenblatt) % | 24.5 | |||||
ROCE % | 12.91 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 10.47 | |||||
PE Ratio without NRI | 10.1 | |||||
Shiller PE Ratio | 31.96 | |||||
Price-to-Owner-Earnings | 18.77 | |||||
PEG Ratio | 0.62 | |||||
PS Ratio | 0.92 | |||||
PB Ratio | 1.68 | |||||
Price-to-Tangible-Book | 2.73 | |||||
Price-to-Operating-Cash-Flow | 9.38 | |||||
EV-to-EBIT | 11.16 | |||||
EV-to-EBITDA | 8.53 | |||||
EV-to-Revenue | 1.16 | |||||
EV-to-FCF | -77.66 | |||||
Price-to-Projected-FCF | 1.99 | |||||
Price-to-Median-PS-Value | 0.79 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.59 | |||||
Price-to-Graham-Number | 1.11 | |||||
Earnings Yield (Greenblatt) % | 8.96 | |||||
FCF Yield % | -1.57 | |||||
Forward Rate of Return (Yacktman) % | 17.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Daewoong Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚©) | 1,375,328.745 | ||
EPS (TTM) (â‚©) | 10649 | ||
Beta | 0.47 | ||
Volatility % | 27.4 | ||
14-Day RSI | 46.53 | ||
14-Day ATR (â‚©) | 2519.487467 | ||
20-Day SMA (â‚©) | 111165 | ||
12-1 Month Momentum % | 1.96 | ||
52-Week Range (â‚©) | 88300 - 127600 | ||
Shares Outstanding (Mil) | 11.51 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Daewoong Pharmaceutical Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Daewoong Pharmaceutical Co Ltd Stock Events
Event | Date | Price(â‚©) | ||
---|---|---|---|---|
No Event Data |
Daewoong Pharmaceutical Co Ltd Frequently Asked Questions
What is Daewoong Pharmaceutical Co Ltd(XKRX:069620)'s stock price today?
When is next earnings date of Daewoong Pharmaceutical Co Ltd(XKRX:069620)?
Does Daewoong Pharmaceutical Co Ltd(XKRX:069620) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |